Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a ...

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine. Click here to read an ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...